Introduction
============

Idiopathic pulmonary fibrosis (IPF) is a severe and lethal interstitial lung disease, which is characterized by progressive dyspnea and distorted lung function ([@b1-mmr-21-06-2321]). The incidence of IPF gradually increases with age, and primarily occurs in individuals between 60--70 years ([@b2-mmr-21-06-2321],[@b3-mmr-21-06-2321]). A study from the United States estimated that the prevalence rate of IPF varied from 14--43 per 100,000 persons ([@b4-mmr-21-06-2321]). However, despite widespread efforts, the etiology and pathogenesis of the disease remain unclear, and effective treatments with limited side effects are urgently required. Currently, novel treatment strategies should aim to combine multiple therapeutic targets to prevent the pathogenesis of IPF ([@b5-mmr-21-06-2321],[@b6-mmr-21-06-2321]).

Due to its complexity, the pathogenic mechanism of IPF are not fully understood. The underlying mechanisms of IPF involve multiple pathways, such as the inflammatory response, epithelial-mesenchymal transition (EMT), apoptosis, oxidative stress ([@b7-mmr-21-06-2321]--[@b9-mmr-21-06-2321]), and developmental processes, which leading to alveolar epithelial cell injury and fibroblast proliferation that consequently leads to excessive deposition of extracellular collagen ([@b10-mmr-21-06-2321]). It has been reported that inflammatory cell accumulation, pro-inflammatory cytokine release, including interleukin-6, tumor necrosis factor-α and transforming growth factor-β, and oxidative stress disorder exacerbate lung injury in bleomycin-induced pulmonary fibrosis ([@b11-mmr-21-06-2321]). The primary pathological features of pulmonary fibrosis are characterized by the damage and apoptosis of pulmonary tissues, excessive proliferation of pulmonary fibroblasts, and mass secretion and accumulation of collagen matrix ([@b12-mmr-21-06-2321]). Although glucocorticoids, colchicines and cyclophosphamides are currently used to treat pulmonary fibrosis, their poor curative effect and high incidence of side effects makes them less desirable ([@b13-mmr-21-06-2321]). This highlights the importance of further study into the pathogenesis of pulmonary fibrosis and the examination of multi-target therapeutic drugs, which may offer a new developmental direction for the treatment of IPF. Traditional Chinese medicine compounds are characterized by their multi-targeting nature and low side effects, which allows for the investigation of more suitable drugs for IPF treatment ([@b14-mmr-21-06-2321]).

Baicalin is the biologically active form of the dried roots of *Scutellaria baicalensis* Georgi, and the major bioactive ingredient of which is flavinoid. The main chemical constituent flavonoid of baicalin has a variety of biological activities, such as including anti-inflammatory ([@b15-mmr-21-06-2321]), antioxidative ([@b16-mmr-21-06-2321]), antithrombotic ([@b17-mmr-21-06-2321]), anti-proliferative ([@b18-mmr-21-06-2321],[@b19-mmr-21-06-2321]) and regulation of apoptosis ([@b20-mmr-21-06-2321]--[@b22-mmr-21-06-2321]). The multiple functions of baicalin have been well-studied in different fields. Moreover, previous studies have shown that baicalin has protective effects on liver fibrosis induced by CCl~4~ ([@b23-mmr-21-06-2321]), and it can inhibit the formation of renal fibrosis ([@b24-mmr-21-06-2321]). Baicalin alleviates silica-induced lung inflammation by suppressing IL-6 and IL-23, which reflect Th17 response and lung fibrosis ([@b25-mmr-21-06-2321]). Baicalin also inhibited BLM-induced pulmonary fibrosis by upregulating adenosine A2a receptor and downregulating transforming growth factor (TGF)-β1 and phosphorylated (p)-ERK1/2 expression ([@b26-mmr-21-06-2321]). These results indicate that baicalin is may be a potential treatment for IPF. Thus, it is of great significance to investigate the specific mechanism and signaling pathway via which baicalin inhibits pulmonary fibrosis, as this may be a theoretical basis for the use of baicalin in the treatment of IPF.

AKT is a serine/threonine protein kinase that is activated by a number of growth factors and cytokines such as TGF-β and IL-6, in a phosphatidylinositol-3 kinase (PI3K)-dependent manner ([@b27-mmr-21-06-2321]). The PI3K/AKT signaling pathway is involved in numerous cellular processes, such as cell differentiation, proliferation, apoptosis and angiogenesis ([@b28-mmr-21-06-2321]--[@b30-mmr-21-06-2321]), and is stimulated by the activation of receptor tyrosine kinases, which leads to the translocation of PI3K from the cytoplasm to the plasma membrane ([@b31-mmr-21-06-2321]). Leptin accelerates EMT of human lung carcinoma A549 cell and promotes pulmonary fibrosis by inhibiting autophagy via the PI3K/AKT/mTOR pathway ([@b32-mmr-21-06-2321]). Furthermore, syndecan-2 attenuates radiation-induced pulmonary fibrosis, and inhibits mouse lung fibroblast migration and proliferation by suppressing PI3K/AKT/Rho-associated protein kinase signaling via CD148 ([@b33-mmr-21-06-2321]). Moreover, the PI3K/AKT pathway activates endoplasmic reticulum (ER) stress and influences lung fibroblast proliferation in BLM-induced pulmonary fibrosis ([@b34-mmr-21-06-2321]).

Calcium/calmodulin-dependent kinase II (CaMKII), which is known as a general integrator of Ca^2+^ signaling, is activated upon binding to Ca^2+^/calmodulin (CaM), which subsequently undergoes autophosphorylation ([@b35-mmr-21-06-2321]). Previous studies have revealed that CaM KII is involved in the pathological course of lung diseases via the modulation of intracellular Ca^2+^ concentrations ([@b36-mmr-21-06-2321],[@b37-mmr-21-06-2321]). It has also been shown that puerarin stimulates endothelial nitric oxide synthase (eNOS) activation, which is mediated by PI3K/AKT and 5′-AMP-activated protein kinase (AMPK) activation via an ER- and CaMKII-dependent pathway ([@b38-mmr-21-06-2321]). Moreover, prostaglandin E~2~ was found to interfere with Ca^2+^ signaling and prevent the activation of AKT and CaMKII in human pulmonary fibroblasts isolated from patients with IPF ([@b39-mmr-21-06-2321]). Ca^2+^ signaling and calmodulin-dependent protein kinase IIβ and IIδ are also involved in TGF-β-induced extracellular matrix gene expression in human pulmonary fibroblasts ([@b6-mmr-21-06-2321]). Additionally, insulin stimulates the proliferation of dermal fibroblasts via activated CaMKII, and induces Raf-1 and ERK expression ([@b40-mmr-21-06-2321]). However, the impact of the PI3K/AKT and CaMKII pathways in baicalin-regulated pulmonary fibrosis and pulmonary fibroblast proliferation is not fully understood, Thus the present study aimed to investigate its role and identify its underlying mechanism. It was hypothesized that CaMKII and PI3K/AKT may be involved in the activation of fibroblast proliferation in the pulmonary fibrosis. In the present study, the protective function of adenosine baicalin and lung fibroblast proliferation were investigated in a BLM-induced pulmonary fibrosis model, to determine whether baicalin suppressed lung fibroblasts proliferation via the inhibition of the CaMKII and AKT signaling pathways.

Materials and methods
=====================

### Materials

BLM was purchased from Nippon Kayaku Co., Ltd., and dissolved in saline to a final concentration of 5 mg/ml. Baicalin (Sigma-Aldrich; Merck KGaA; purify, \>95%) was prepared in physiological saline at a 2% concentration. The superoxide dismutase (SOD), glutathione peroxidase (GSH-px), malondialdehyde (MDA) and hydroxyproline (Hyp) kits were purchased from the Nanjing Jiancheng Bioengineering Institute. The TUNEL Apoptosis Assay kit was purchased from Roche Diagnostics. Antibodies against Bcl-2 and cyclin A were acquired from Beyotime Institute of Biotechnology. Antibodies against caspase-3, Bax, cyclin D, cyclin E, proliferating cell nuclear antigen (PCNA), phosphorylated (p)-AKT, total (t)-AKT, p-CaMKII, t-CaMKII and β-actin were acquired from Cell Signaling Technology, Inc. The Cell Cycle and Apoptosis Analysis kit (cat. no. C1052) was purchased from the Beyotime Institute of Biotechnology, and ECL reagents were obtained from GE Healthcare.

### Animal model and experimental protocol

Adult female Wistar rats (age, 42--49 days; weight, 160--200 g) used in this study were purchased from the Animal Research Center of Harbin Medical University, which is fully accredited by the Institutional Animal Care and Use Committee. All animals were housed in cages, in a 12:12h light/dark cycle, the temperature at 24°C, and humidity of 50--70%, allowed free access to food and water. All experiments were approved by the Animal Care Committee of China Medical University. The animals were randomized into the following four groups (n=6/group): i) The sham group; ii) the sham + baicalin group; iii) the BLM group; and iv) the BLM + baicalin group. The pulmonary fibrosis model was prepared as previously reported ([@b41-mmr-21-06-2321]). Briefly, the rats were anesthetized with an intraperitoneal injection of 1% pentobarbital sodium (50 mg/kg), and then treated with a single intratracheal instillation of 5 mg/kg BLM solution. The sham group rats received intratracheal injection of an equal volume of the sterilized saline. The following day, 50 mg/kg baicalin was intraperitoneally administered, which was continued once a day for 28 days, and six animals per group were sacrificed on day 29. The rats were anesthetized with 1% pentobarbital sodium (50 mg/kg), the blood and bronchial alveolar lavage fluid were collected, and the lungs were removed for subsequent experimentation. After sampling, the rats were euthanized by overdose anesthesia. Blood was collected from the abdominal aorta under anesthesia and centrifuged at 2,411 × g for 5 min at room temperature, and the serum was then stored at −20°C until use. The left lung of each animal was morphologically assessed, the right lung was stored at −80°C and the Hyp content was determined using a commercial assay kit, according to the manufacturer\'s instructions.

### Histology

The left lung was perfused with 4% paraformaldehyde (PFA) at a pressure of 25 cm H~2~O via the left principal bronchus at room temperature, and immersed in PFA solution overnight following the tracheal ligation. Subsequently, the lung tissues were embedded in paraffin, and cut into 4-µm thick serial sections. Then, 2 min hematoxylin and eosin (H&E) staining, as well as 8 min Masson staining were performed at room temperature to determine the degree of alveolitis and fibrosis, and the sections were observed by light microscopy (magnification, ×10).

### Measurement of Hyp content

Frozen lungs (\~100 mg) were cut into fragments and then ground using a glass homogenizer on ice. The Hyp content of the lung tissue was assessed using the Hyp ELISA kit (cat. no. A030-3-1; Nanjing Jiancheng Bioengineering Institute), according to the manufacturer\'s protocol. Lung tissues were hydrolyzed at 100°C for 20 min, and adjusted to a preset pH. The mixture was incubated at 60°C for 15 min and centrifuged at 2,813 × g for 10 min in room temperature after cooling. The absorbance of each sample at 550 nm was determined, and the data were calculated as µg Hyp per mg wet lung weight.

### Bronchial alveolar lavage fluid (BALF) cell count

The right lung of each animal was ligated at the hilus, and an 18-gauge catheter was inserted into the trachea and placed in the left main bronchus. BALF was obtained by cannulating the trachea and injecting and retrieving three 3 ml aliquots of sterile saline, the fluid was then centrifuged at 1,205 × g for 15 min at 4°C, and the supernatants were discarded. The cell pellets were resuspended in PBS and the total number of cells was counted using a hemocytometer.

### Measurement of MDA content, total-SOD (T-SOD), GSH-px and GSH activities in serum

The enzymatic activities of SOD and GSH, and the MDA content were assessed using different commercial assay kits in accordance with the manufacturer\'s instructions. The serum content of T-SOD was determined using the T-SOD assay kit (cat. no. A001-1-2; Nanjing Jiancheng Bioengineering Institute), according to the manufacturers instructions. SOD activity was detected in serum by measuring the ability to inhibit the photochemical reduction of nitro blue tetrazolium (NBT); the optical density was measured at 550 nm and the data were expressed as µ/ml.

GSH and GSH-px activity were analyzed using commercial kits per the manufacturer\'s protocols (GSH, cat. no. A006-2-1; GSH-px, cat. no. A005-1-2; Nanjing Jiancheng Bioengineering Institute), which were based on the consumption of reduced glutathione. Absorbance was determined at 412 nm and the levels of GSH and GSH-px were defined as µ/ml.

The serum MDA concentration was detected by measuring the degradation product of thiobarbituric acid at a maximum wavelength of 532 nm, according to the manufacturer\'s instructions (MDA, cat. no. A003-1-2; Nanjing Jiancheng Bioengineering Institute). Serum samples (100 µl) were supplemented with 5 mg/ml butylated hydroxytoluene to prevent artificial lipid peroxidation. The samples were then centrifuged (1,600 × g, 10 min, 4°C) to remove insoluble material, and 100 µl supernatants were transferred to a microcentrifuge tube and supplemented with 800 µl thiobarbituric acid (TBA) to generate an MDA-TBA adduct. To accelerate the process, samples were incubated at 95°C for 60 min, placed on an ice bath for 10 min to inhibit the reaction and centrifuged (1,600 × g, 10 min, 4°C). The final product was measured colorimetrically at 532 nm, and the absorbance values were compared to a calibration curve prepared using the MDA standard; data were expressed as nmol/ml.

### Measurement of TGF-β1 and TNF-α detection in BALF

The concentrations of TGF-β1 and TNF-α in the BALF were determined using the Rat TGF-β1 and TNF-α ELISA kits (Rat TGF-β1 ELISA kit, cat. no. PT878; Rat TNF-α ELISA kit, cat. no. PT516) according to the manufacturer\'s instructions. Samples or reference standards (100 µl) were added to each well of a microplate precoated with biotinylated antibody 100 µl specific to TGF-β1 or TNF-α and incubated at room temperature for 60 min. After washing out unbounded proteins, a horseradish peroxidase (HRP)-conjugated polyclonal secondary antibody was added to the wells (100 µl/well) and incubated for 30 min at room temperature in the dark. After washing with the washing reagent from the kit and 100 µl developer 3,3′,5,5′-Tetramethylbenzidine solution was added at room temperature for 20 min in the dark, as well as 50 µl termination solution, optical density was determined at 450 nm. The results were quantified using the linear regression equation of the standard curve.

### TUNEL assay

The detection procedure was performed according to the manufacturer\'s instructions, but with modifications. Deparaffinized 4-µm-thick tissue sections were treated with 20 µg/ml proteinase K for 15 min at room temperature. Subsequently, the TUNEL reagent containing dUTP and TdT (Roche Diagnostics) was added to each section, and incubated in a humidified chamber at 37°C for 60 min. The sections were rinsed with PBS and the sections were incubated with 0.3% converter-peroxidase for 30 min at 37°C, then the sections rinsed with PBS prior to the addition of DAB substrate 10 min at room temperature and color rendering was observed under the microscope for 3--8 min. After the color development with tap water, sections were rinsed for 15 min and hematoxylin staining was performed for 2 min at room temperature, and subsequent steps were performed as follows. At the room temperature, the sections rinsed with tap water and differentiated with hydrochloric acid alcohol for 3--8 sec, then the slices were immersed in 70% alcohol at 5 min, 80% alcohol at 5 min, 90% alcohol at 5 min and 100% alcohol at 5 min twice, soaked in xylene at 10 min twice, and sealed with neutral balsam. All specimens were examined by two pathologists who were blinded to the experimental protocol. The sections were observed by light microscopy (magnification, ×10).

### Isolation of rat primary lung fibroblasts

Normal rat primary fibroblasts from female Wistar rats were prepared and cultured as previously described ([@b42-mmr-21-06-2321]). The cells were cultured in DMEM containing 15% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a 5% CO~2~ incubator. Upon reaching confluence, the cells were trypsinized, counted, seeded into culture flasks at a density of 10^4^/ml and used in the following experiments. All experiments were performed using cells between passages 2 and 6.

### Western blotting

Lung tissues and fibroblasts were homogenized in cold RIPA lysis buffer, which contained 50 mM Tris (pH 7.4),150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM EDTA and 1 µg/ml leupeptin. Total protein was quantified using a bicinchoninic acid assay kit. The western blot protocol was an adaptation of a previously described ([@b43-mmr-21-06-2321]). Briefly, equal amounts of protein (50 µg per lane) were separated on 10% SDS-PAGE gels and electro-blotted onto nitrocellulose membranes (EMD Millipore). The membranes were then blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 (TBS-T) for 1 h at room temperature, and incubated at 4°C overnight with the following primary antibodies: Anti-Bcl-2 (1:500; cat. no. AB112), anti-Bax (1:500; cat. no. 2772), anti-caspase-3 (1:200; cat. no. 9661), anti-cyclin A (1:500; cat. no. AF2524), anti-cyclin D (1:500; cat. no. 2922), anti-cyclin E (1:500; cat. no. 20808), anti-PCNA (1:500; cat. no. 2586), anti-p-AKT (1:500; cat. no. 9271), anti-t-AKT (1:500; cat. no. 9272), anti-p-CaMKII (1:500; cat. no. 12716) and anti-t-CaMKII (1:500; cat. no. 3362). The primary antibodies were purchased from Cell Signaling Technology, Inc and the Beyotime Institute of Biotechnology. After three rinses with TBS-T for 10 min each, the membranes were incubated with HRP-conjugated secondary antibodies (mouse; 1:5,000; cat. no. ZB2305; rabbit; 1:5,000; cat. no. ZB2301; Zhongshan Golden Bridge Bio-technology) for 1 h at room temperature. For immunodetection, the membranes were incubated with ECL reagents (Applygen Technologies, Inc.). Protein expression was semi-quantified using Quantity One software (version 4.6.2; Bio-Rad Laboratories, Inc.) with β-actin and GAPDH as the loading controls.

### MTT assay

Fibroblasts (1×10^4^ cells/well) were cultured in 96-well microtiter plates with serum-free DMEM for 24 h to induce growth arrest at 37°C in a 5% CO~2~ incubator. BLM and baicalin were diluted in PBS and then purified using a filter with a 0.22-µm pore size (Millex-GS; EMD Millipore). Then, 190 µl filtered PBS was added to DMEM in each control group. The cells were incubated with 190 µl different concentrations of BLM (0.1, 1.0, 10, 20 or 40 µg/ml) and baicalin (20, 40, 60 or 80 µg/ml) for 24 h at 37°C in a 5% CO~2~ incubator and treated for 4 h in medium containing 0.5% MTT 10 µl (at 37°C). After removing the supernatant, 150 µl dimethyl sulfoxide was added to each well and the plates were mixed on a plate shaker for 10 min at room temperature. The absorbance of each sample was determined using a microplate reader at 490 nm.

### Cell cycle analysis

To study alterations to the cell cycle induced by BLM, the proportion of fibroblasts in the G~0~/G~1~, S and G~2~/M phases was analyzed by flow cytometry, as previously reported ([@b44-mmr-21-06-2321]). The detection procedure was performed according to the manufacturer\'s instructions, using a Cell cycle and apoptosis detection kit (Beyotime Institute of Biotechnology; cat. no. C1052). Following drug treatment at special time intervals, the cells were subjected with harvested by trypsinization, centrifuged at 300 × g for 5 min at room temperature and then resuspended in 1 ml cold PBS. Following two washes with PBS, the cells were resuspended and fixed using 70% cold ethanol and stored at 4°C for ≥2 h until use. Prior to cell cycle analysis, the fixed cells were centrifuged at 300 × g for 5 min at room temperature, and the supernatant was discarded. Each sample was resuspended in a mixed solution at room temperature, which contained 500 µl staining buffer, 10 µl RNase A and 25 µl propidium iodide. Then, the suspension was mixed and incubated at 37°C for 30 min in the dark. Cells were filtered using 400-mesh sieves prior to analysis using a flow cytometer (C6 type; BD Biosciences). The data of the experiment was exported to Excel 2007 (Microsoft Corporation) and SPSS 19.0 (SPSS, Inc.) was used to analyze the statistical significance.

### Measurement of \[Ca^2+^\]~i~

Fibroblasts at a density of 10^4^/ml were incubated with a working solution containing 10 mM Fluo-3/AM (acetoxymethyl ester; Molecular Probes; Thermo Fisher Scientific, Inc.) and 0.03% PluronicF-127, at 37°C for 40 min. The cells were then rinsed twice with Tyrode solution to move any remaining dye. Changes in \[Ca^2+^\]~i~ levels were indicated by fluorescence intensity (FI). The cellular FI of Fluo-3/AM was detected for 5 min using a laser scanning confocal microscope (magnification, ×10; Olympus Corporation) with an emission wavelength of 530 nm and excitation wavelength of 488 nm. FI was assessed in 10 randomly selected cells, and the average intensity was determined.

### Statistical analysis

Data were analyzed using SPSS 19.0 ([@b45-mmr-21-06-2321]) and are presented as the mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey\'s test, which was used for the comparison of \>3 groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baicalin attenuates lung fibrosis, and reduces Hyp content and collagen protein expression in a BLM-induced rat model of pulmonary fibrosis

A significant increase in the Hyp content was observed following BLM administration in the model group, compared with the sham group ([Fig. 1A](#f1-mmr-21-06-2321){ref-type="fig"}). However, this was significantly inhibited by treatment with 50 mg/kg baicalin, which had no significant effect on the sham group. To further investigate the effects of baicalin in the pathogenesis of BLM-induced lung fibrosis, lung tissue morphology was examined by H&E and Masson staining. At day 28, the lung tissues of BLM group exhibited severe fibrosis compared with the sham group ([Fig. 1B](#f1-mmr-21-06-2321){ref-type="fig"}), which included inflammatory cell infiltration and alveolar hemorrhage. It was also found that the alveoli were enlarged and the alveolar interstitium was thickened, as indicated by yellow arrows. Furthermore, Masson\'s staining demonstrated abundant collagen deposition (yellow arrows; [Fig. 1C](#f1-mmr-21-06-2321){ref-type="fig"}). Treatment with 50 mg/kg baicalin significantly reduced BLM-induced pathological changes, which included collagen deposition, and damage to the lung structure and interstitium. However baicalin treatment did not have a significant effect on the sham group ([Fig. 1B and C](#f1-mmr-21-06-2321){ref-type="fig"}). Baicalin also suppressed the BLM-induced expression of collagen I and III ([Fig. 1D and E](#f1-mmr-21-06-2321){ref-type="fig"}). The results suggested that baicalin had a protective role during BLM-induced pulmonary fibrosis and lung tissue apoptosis.

### Baicalin attenuates the inflammatory response, and decreases TGF-β1 and TNF-α expression levels in a rat model of BLM-induced pulmonary fibrosis

At day 28, the total number of cells in the BALF of rats treated with BLM (5 mg/kg) and baicalin (B50 mg/kg) was determined. The total number of cells in the BLM-treated group was significantly increased (5.26±0.31) compared with the sham group (4.07±0.34; [Fig. 2A](#f2-mmr-21-06-2321){ref-type="fig"}). However, the increase in the total cell number was decreased by the application of 50 mg/kg baicalin (4.76±0.24), while there was no significant difference between the sham group and the sham + baicalin 50 mg/kg group (4.12±0.36). The expression levels of TGF-β1 and TNF-α in the BALF were quantified by ELISA, which revealed that both TGF-β1 and TNF-α were significantly upregulated in the BALF of the BLM group (65.92±2.1 and 394±15, respectively) compared with the sham group (37.68±1.6 and 324±12, respectively). However, baicalin significantly decreased TGF-β1 and TNF-α expression (51.2±1.9 and 364±12, respectively) in BLM-treated rats. Moreover, baicalin did not affect the expression of TGF-β1 and TNF-α under sham conditions (38.01±1.7 and 336±13, respectively; [Fig. 2B and C](#f2-mmr-21-06-2321){ref-type="fig"}).

### Baicalin attenuates oxidative stress-associated damage

To investigate whether baicalin contributes to oxidative stress, the activities of GSH-px, T-SOD and GSH, as well as the serum MDA content were determined. It was demonstrated that GSH-px, T-SOD and GSH activities were decreased significantly in the serum of the 5 mg/kg BLM group (738±13, 186±11 and 795±26, respectively) compared with the sham group (809±14, 224.7±13 and 945±25, respectively; [Fig. 3A-C](#f3-mmr-21-06-2321){ref-type="fig"}). However, treatment with 50 mg/kg baicalin significantly increased the activities of GSH-px, T-SOD and GSH (769±18, 212±12 and 838±23, respectively). Furthermore, the level of serum MDA, an index of lipid peroxidation ([@b46-mmr-21-06-2321]) was significantly increased in the 5 mg/kg BLM group (5.39±0.47) compared with the sham group (4.33±0.33; [Fig. 3D](#f3-mmr-21-06-2321){ref-type="fig"}), after the administration of 50 mg/kg baicalin, BLM-mediated lipid peroxidation was significantly decreased (4.69±0.39). However, 50 mg/kg baicalin had no obvious effect on oxidative damage in the sham group (4.29±0.36).

### Baicalin inhibits BLM-induced apoptotic protein expression in rat lung tissues

To investigate whether baicalin is involved in lung tissue apoptosis, TUNEL staining was conducted. Compared with the sham group, a significant increase in TUNEL-positive cells (yellow arrows) was observed in the BLM group ([Fig. 4A and B](#f4-mmr-21-06-2321){ref-type="fig"}). Furthermore, the administration of 50 mg/kg baicalin inhibited the appearance of TUNEL-positive cells in the BLM group, which was indicated in the yellow arrows, but not the sham group. In addition, the mechanism of baicalin-induced lung tissue apoptosis was investigated. Bcl-2 and Bax are localized on the mitochondrial membrane and play important roles in apoptosis ([@b47-mmr-21-06-2321]). Bcl-2 is known to be anti-apoptotic, whereas Bax is a pro-apoptotic protein ([@b47-mmr-21-06-2321]). Therefore, in the present study, the effect of baicalin on the protein expression levels of Bcl-2 and Bax were investigated. The data showed that the expression levels of Bcl-2 were downregulated, while that of Bax was upregulated by BLM. Moreover, baicalin (50 mg/kg) increased Bcl-2, and suppressed Bax protein expression in rat lung tissues ([Fig. 4C and D](#f4-mmr-21-06-2321){ref-type="fig"}). Pro-caspase-3 is cleaved and activated to form caspase-3 by originator caspases (including caspase 2, 8, 9, 10, 11 and 12) in response to apoptotic stimuli ([@b48-mmr-21-06-2321]). In addition, BLM promoted the protein expression of caspase-3, an effect which was primarily blocked by 50 mg/kg baicalin treatment ([Fig. 4E](#f4-mmr-21-06-2321){ref-type="fig"}). However, baicalin had no significant effect on the expression of Bcl-2, Bax and caspase-3 in the sham group.

### Baicalin reverses BLM-induced fibroblast proliferation, cyclin protein expression and cell cycle progression in vivo

Following BLM treatment, MTT was used to examine the effect of baicalin on the viability of rat lung fibroblasts. After a 24-h treatment period (1.0, 10, 20 or 40 µg/ml BLM) caused a significant dose-dependent increase in lung fibroblast viability, compared with that of the control group ([Fig. 5A](#f5-mmr-21-06-2321){ref-type="fig"}). With regards to the safety of the drug, 20 µg/ml BLM was selected for the following experiments. To demonstrate the effect of baicalin on lung fibroblasts, the dose-dependent effect was examined. Treatment with 40, 60 or 80 µg/ml baicalin reduced cell viability at 24 h, while 20 µg/ml baicalin failed to reduce cell viability under 20 µg/ml BLM treatment. Among the different treatment doses, 80 µg/ml baicalin exerted the most significant inhibitory effect ([Fig. 5B](#f5-mmr-21-06-2321){ref-type="fig"}). Therefore, unless otherwise stated, all subsequent experiments were performed under these conditions (24 h, 20 µg/ml BLM and 80 µg/ml baicalin). Western blot analysis was conducted to observe the expression levels of cyclin proteins in lung fibroblasts treated with 80 µg/ml baicalin. The results indicated that 20 µg/ml BLM significantly increased the expression of cyclin A, cyclin D, cyclin E, as well as PCNA in rat fibroblasts ([Fig. 5C-F](#f5-mmr-21-06-2321){ref-type="fig"}). CaMKII is reported to be activated by intracellular Ca^2+^ ([@b35-mmr-21-06-2321]), and the western blot results indicated a significant increase in p-AKT and p-CaMKII expression levels in the BLM group ([Fig. 6A and B](#f6-mmr-21-06-2321){ref-type="fig"}). However, 80 µg/ml baicalin suppressed the expression of cyclin A, D and E, PCNA, p-AKT and p-CaMKII ([Figs. 5C-F](#f5-mmr-21-06-2321){ref-type="fig"} and [6A and B](#f6-mmr-21-06-2321){ref-type="fig"}).

Additionally, BLM increased the percentage of cells in the S and G~2~/M phases of the cell cycle. Baicalin inhibited fibroblast cell cycle progression and promoted arrest at the G~0~/G~1~ phase ([Fig. 6C](#f6-mmr-21-06-2321){ref-type="fig"}). Moreover, laser scanning confocal microscopy indicated that the increase in \[Ca^2+^\]~i~ in BLM-treated fibroblasts was significantly attenuated by baicalin treatment ([Fig. 6D and E](#f6-mmr-21-06-2321){ref-type="fig"}). The results suggested that baicalin protected cell cycle activity and inhibited fibroblast proliferation, ultimately contributing to pulmonary fibrosis.

Discussion
==========

Pulmonary fibrosis is the final stage of several diffuse parenchymal lung diseases, and is characterized by excessive matrix deposition and destruction of the lung architecture, eventually resulting in respiratory insufficiency ([@b49-mmr-21-06-2321]). IPF is a progressive, end stage disease, and the pathophysiological basis of the disease has been a topic of debate over the last few decades ([@b8-mmr-21-06-2321]). Animal models of BLM-induced lung fibrosis are widely used to study IPF ([@b50-mmr-21-06-2321]), though the precise mechanism of IPF is still unclear. Previous studies have demonstrated that baicalin exhibits strong antitumor activity and inhibits apoptosis of tumor cells ([@b51-mmr-21-06-2321]--[@b53-mmr-21-06-2321]). Therefore, in the present study, the mechanisms underlying the effect of baicalin on pulmonary fibrosis was investigated, demonstrating that baicalin reversed BLM-induced lung tissue apoptosis and pulmonary fibrosis, attenuated oxidative stress and inhibited rat lung fibroblast proliferation, at least partly via the CaMKII and AKT pathways.

In a short period of time, BLM can induce inflammatory and fibrotic aberrations in the lung tissue, and intratracheal administration of BLM has been shown to increase the expression of fibrogenic cytokines such as TNF-α, TGF-β, IL-1β and IL-6 ([@b50-mmr-21-06-2321]). Pathological changes due to lung tissue inflammation were also observed in the present study, after exposure to BLM, a rapid increase in Hyp content and the infiltration of inflammatory cells was apparent, and alveolar septal thickening was indicated by H&E and Masson staining. Conversely, rats in the BLM + baicalin group exhibited reduced inflammatory cell infiltration and collagen deposition in the lungs. In addition to a reduction in collagen I and III protein expression following baicalin treatment, these results indicated that baicalin attenuated BLM-induced pulmonary fibrosis.

Following administration of 5 mg/kg BLM, which emulates inflammatory stimulation ([@b54-mmr-21-06-2321]), the total number of cells in the BALF was significantly increased, which was subsequently reduced by baicalin treatment (5 mg/kg). Previous studies have revealed that TNF-α is overexpressed in the fibrotic lung tissues of animal models of BLM-induced pulmonary fibrosis ([@b55-mmr-21-06-2321]--[@b57-mmr-21-06-2321]), which serves a vital role in fibrotic progression ([@b58-mmr-21-06-2321]). TGF-β1 is also a crucial profibrotic cytokine ([@b59-mmr-21-06-2321],[@b60-mmr-21-06-2321]) and plays a central role in the mechanism of systemic sclerosis-associated pulmonary fibrosis ([@b61-mmr-21-06-2321],[@b62-mmr-21-06-2321]). In the present study, baicalin was identified to inhibit the expression of TGF-β1 and TNF-α in the BALF of the BLM group. These results suggested that baicalin attenuates the pulmonary inflammation induced by BLM. Additionally, Moreover, the present results indicated that baicalin can significantly alleviated pulmonary fibrosis and inflammatory responses induced by BLM in rats. However, the anti-pulmonary fibrosis effect of baicalin has also been reported in other species and strains. Liu *et al* reported that baicalin alleviated silica-induced lung inflammation by suppressing IL-6 and IL-23, which reflects Th17 response and lung fibrosis in C57BL/6 mice ([@b25-mmr-21-06-2321]). Baicalin inhibited BLM-induced pulmonary fibrosis in mice by upregulating Adenosine A2a receptor and downregulating TGF-β1 and p-ERK1/2 expression ([@b26-mmr-21-06-2321]). The cross-species effect of baicalin also suggested that future studies should investigate the specific mechanism and underlying signaling pathways of baicalin in inhibiting pulmonary fibrosis in a murine model.

Previous studies have suggested that oxidative stress contributes to fibrosis in a variety of organs ([@b63-mmr-21-06-2321],[@b64-mmr-21-06-2321]), and that there is an imbalance between the generation of ROS ([@b65-mmr-21-06-2321]--[@b67-mmr-21-06-2321]). Therefore, in the present study, oxidative stress was assessed by detecting GSH-px, T-SOD and GSH activity, as well as the levels of MDA in the serum of fibrotic rats. It was demonstrated that in the BLM group, MDA levels were significantly increased, while GSH-px, T-SOD and GSH levels were reduced. By contrast, baicalin significantly reduced the MDA content, and simultaneously increased the levels of GSH-px, T-SOD and GSH. The results implied that baicalin significantly suppressed BLM-induced fibrosis and oxidative stress injury, which may explain the protective effects against BLM-induced pulmonary fibrosis.

The mechanisms of baicalin-associated lung tissue apoptosis were also investigated following BLM administration. Morphological evaluation demonstrated that 50 mg/kg baicalin decreased the number of TUNEL-positive cells in the lung tissue. Furthermore, the down-regulation of BLM-induced Bcl-2 expression was significantly reversed by baicalin treatment. Baicalin also reversed the BLM-associated increase in Bax and caspase-3 expression levels, thus demonstrating that baicalin protects against apoptosis in pulmonary tissues.

Fibroblasts are critical cells for the pathogenesis of pulmonary fibrosis ([@b68-mmr-21-06-2321]). In the present study, it was demonstrated that BLM promoted rat lung fibroblast viability in dose-dependent manner. Similar results have been reported in other studies. F2-isoprostanes mediated BLM (25, 50 and 100 µg/ml) induced rat lung fibroblast proliferation and collagen synthesis, and the incubation time of bleomycin was 48 h ([@b69-mmr-21-06-2321]). Additionally, NLRP3 participates in the regulation of epithelial-mesenchymal transition (EMT) in BLM-induced pulmonary fibrosis, the concentrations of bleomycin was treated to A549 cells were 0, 40, 80, 120, 160 and 200 µM for 24 h to study cell viability, and those added to RLE-6TN cells were 0, 10, 20, 30, 40, 50 and 60 µM for 24 h ([@b70-mmr-21-06-2321]). It has been shown that different cell types may be differentially effected by the same drug. In the present study, cell viability assays revealed that fibroblast proliferation was consistent at 20 and 40 µg/ml BLM, thus, 20 µg/ml BLM treatment for 24 h was utilized for subsequent experimentation. Following the administration of different concentrations of baicalin (40, 60 and 80 µg/ml), the results indicated that 40, 60 and 80 µg/ml baicalin significantly reduced lung fibroblast viability in the 20 µg/ml BLM group, however, no significant effect was observed following treatment with 20 µg/ml baicalin. It has been reported that baicalin treatment (50 or 100 µM for 24 h) promoted the repair of DNA single-strand breaks and improved cell viability in H~2~O~2~-treated NIH3T3 mouse fibroblasts ([@b71-mmr-21-06-2321]). Furthermore, baicalin (25, 50 and 100 µg/ml) reduced the colistin sulfate-induced apoptosis of PC12 cells in a dose-dependent manner ([@b72-mmr-21-06-2321]). Additionally, baicalin (200 µM) activated caspase-3 expression to induce apoptosis in SW620 human colorectal carcinoma cells ([@b73-mmr-21-06-2321]). In clinical practice, baicalin displays good drug safety, and the present study further suggested that 80 µg/ml baicalin significantly reduced the viability of lung fibroblasts.

The cell cycle plays an important role in cell proliferation ([@b74-mmr-21-06-2321]), but how the cell cycle progression responds to the baicalin remains unknown. The cell cycle is subdivided into four phases: DNA replication occurs during S phase, and chromosome segregation occurs during M phase. The S and M phases are separated by G~1~ (before DNA replication) and G~2~ (before mitosis) ([@b75-mmr-21-06-2321]). Cyclin A is essential for progression through the S phase, and cyclin D and E, are necessary for G~1~/S transition ([@b76-mmr-21-06-2321]--[@b78-mmr-21-06-2321]). The results of the present study demonstrated that BLM increased the expression of cyclin A, D and E, and PCNA *in vitro*, and increased the proportion of cells in the S and G~2~/M phases, suggesting that BLM induces proliferation via the cell cycle. *In vitro*, baicalin (20 µg/ml) decreased the BLM-induced protein expression levels of cyclin A, D and E, and PCNA, and the proportion of cells in the S and G~2~/M phases. The PI3K/AKT pathway is involved in the regulation of several target proteins such as NF-κB, p53, glycogen synthase kinase-3β, Bad and caspase-9 that regulate cellular proliferation and apoptosis ([@b43-mmr-21-06-2321]). Immunohistochemical analysis of lung biopsy specimens from patients with IPF revealed that fibroblasts within fibrotic foci expressed low levels of PTEN and upregulated levels of AKT ([@b79-mmr-21-06-2321]). Fucoxanthin inhibited the TGF-β1-induced expression of α-SMA, type 1 collagen and IL-6, and inhibited the phosphorylation of p38, PI3K/AKT and Smad2/Smad3 in human pulmonary fibroblasts ([@b80-mmr-21-06-2321]). Additionally, small interfering RNAs (siRNAs) against plasminogen activator inhibitor-1 (PAI-1) reduced the expression of type I and III collagen and increased the expression of caspase-3 *in vivo*, as well as inhibiting p-ERK1/2 and PI3K/AKT expression, and induced the proliferation of fibroblasts derived from rat models of BLM-induced fibrosis ([@b81-mmr-21-06-2321]). It has also been shown that microRNA (miR)-155 reduces the expression of collagens and inhibits the formation of hypertrophic scar fibroblasts by targeting hypoxia-inducible factor-1α via the PI3K/AKT signaling pathway ([@b82-mmr-21-06-2321]). Additionally, activation of the adenosine subtype 2B (A2B) receptor mediated the inhibition of ET-1-induced fibroblast proliferation via the cAMP/Epac/PI3K/AKT signaling pathway ([@b83-mmr-21-06-2321]). miR-542-5p mimic reduced the proliferation of mouse fibroblasts, and inhibited silica-induced pulmonary fibrosis by directly binding to integrin-α6, both effects at least partially via the FAK/PI3K/AKT signaling pathway ([@b84-mmr-21-06-2321]). However, whether PI3K is involved in the effect of baicalin on pulmonary fibrosis, and its specific BLM-induced mechanism, has not yet been reported.

CaMKII is known to be activated by intracellular Ca^2+^ ([@b35-mmr-21-06-2321]). He *et al* ([@b85-mmr-21-06-2321]) reported that LPS induced a direct fibrogenic effect on lung fibroblasts by upregulating collagen expression and cell proliferation via the PI3K/AKT signaling pathway. However, the relationship between baicalin and the PI3K/AKT or CaMKII signaling pathways in pulmonary fibrosis has not been elucidated. The results of the present study suggested that BLM increased the phosphorylation of CaMKII and AKT, which was reversed by baicalin treatment. Moreover, baicalin significantly decreased BLM-induced \[Ca^2+^\]~i~ in lung fibroblasts. The results suggested that the CaMKII and AKT signaling pathways were involved in the inhibition of the cell cycle and proliferation of lung fibroblasts in rats treated with baicalin. Consistently, it has been reported that in certain cell types, Ca^2+^/calmodulin-dependent protein kinases act upstream of AMPK ([@b86-mmr-21-06-2321],[@b87-mmr-21-06-2321]). Moreover, puerarin-mediated eNOS phosphorylation is dependent on AMPK signaling via CaMKII ([@b38-mmr-21-06-2321]). An increase in ERK1/2 expression promotes CaMKII-induced matrix metalloproteinase-9 expression, resulting in the proliferation and migration of cardiac fibroblasts obtained from a rat model of pulmonary arterial hypertension ([@b88-mmr-21-06-2321]). Furthermore, neokyotorphin induced the proliferation of fibroblasts, which required Ca^2+^ influx and the activation of PKA, CaMKII and MAPK/ERK ([@b89-mmr-21-06-2321]).

Although the present study suggested that the protective effect of baicalin on pulmonary fibrosis may be via inhibiting the PI3K/AKT and CaMKII signaling pathways, the receptor and downstream target genes of these inhibitory signaling pathways, the mechanism in baicalin-treated cells requires further investigation. Thus, further studies will help to reveal how baicalin influences the CaMKII/PI3K/AKT complex.

In conclusion, the present study suggested that baicalin inhibited histopathological damage and lung fibroblast proliferation in BLM-induced pulmonary fibrosis, and that this effect was at least in part, mediated via the CaMKII and PI3K/AKT signaling pathways. The present results provide novel insights into the protective effects of baicalin in pulmonary fibrosis and the underlying mechanisms, which may become the theoretical basis for the use of baicalin in the management of IPF.
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![Baicalin attenuates lung fibrosis, Hyp content and collagen expression in a rat model of BLM-induced pulmonary fibrosis. (A) Effect of 50 mg/kg baicalin on Hyp content. Lung tissue morphology was examined by (B) hematoxylin-eosin staining and (C) Masson staining. The yellow arrows indicate morphological damage to the lung. Scale bar, 50 µm. (D) Collagen I and (E) collagen III protein expression were measured using western blot. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 vs. the sham group. ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. the BLM group. Hyp, hydroxyproline; Sham, sham group; BLM, bleomycin; B50, 50 mg/kg baicalin.](MMR-21-06-2321-g00){#f1-mmr-21-06-2321}

![Baicalin reduces the inflammatory response, and TGF-β1 and TNF-α expression levels in BLM-induced pulmonary fibrosis. (A) Total number of cells in the BALF of rats treated with BLM (5 mg/kg) and baicalin (50 mg/kg). Expression levels of (B) TGF-β1 and (C) TNF-α in BALF, determined by ELISA. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 vs. the sham group. ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. the BLM group. TGF, transforming growth factor; TNF, tumor necrosis factor; BALF, bronchial alveolar lavage fluid; Sham, sham group; BLM, bleomycin; B50, 50 mg/kg baicalin.](MMR-21-06-2321-g01){#f2-mmr-21-06-2321}

![Baicalin decreases BLM-induced oxidative stress damage. The effect of 50 mg/kg baicalin on (A) GSH-px, (B) T-SOD and (C) GSH activities, and (D) the MDA content of lung tissues. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 vs. the sham group. ^\#\#^P\<0.01 vs. the BLM group. BLM, bleomycin; GSH-px, glutathione peroxidase; T-SOD, total superoxide dismutase; GSH, glutathione; MDA, malondialdehyde; Sham, sham group; BLM, bleomycin; B50, 50 mg/kg baicalin.](MMR-21-06-2321-g02){#f3-mmr-21-06-2321}

![Baicalin inhibits BLM-induced alterations to apoptotic protein expression in the lung tissues of a rat model of BLM-induced pulmonary fibrosis. (A) TUNEL staining and (B) quantification of lung tissue sections. The yellow arrows indicate TUNEL-positive cells. Scale bar, 50 µm. (C) Bax expression in BLM-treated rats was decreased by 50 mg/kg baicalin. (D) Effect of baicalin treatment on Bcl-2 expression. (E) BLM-induced caspase 3 expression was decreased by 50 mg/kg baicalin. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 vs. the sham group. ^\#\#^P\<0.01 vs. the BLM group. Sham, sham group; BLM, bleomycin; B50, 50 mg/kg baicalin.](MMR-21-06-2321-g03){#f4-mmr-21-06-2321}

![Baicalin reverses BLM-induced fibroblast proliferation, and the expression of PI3K/AKT and CaMKII *in vivo*. Lung fibroblasts were growth-arrested for 24 h and subsequently treated with different concentrations of BLM (0.1, 1.0, 10, 20 and 40 µg/ml). (A) Effect of BLM on lung fibroblast viability. (B) Dose-dependent effects of baicalin (20, 40, 60 and 80 µg/ml) on lung fibroblast viability under the treatment of BLM (20 µg/ml). BLM-induced (20 µg/ml) upregulation of (C) cyclin A, (D) cyclin D, (E) cyclin E and (F) PCNA protein expression was reduced by baicalin (80 µg/ml) in lung fibroblasts. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 and \*\*P\<0.01 vs. the Con group. ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. the BLM group. Con, control; BLM, bleomycin; BL, bleomycin; CaMKII, calcium/calmodulin-dependent kinase II; PCNA, proliferating cell nuclear antigen; BL0.1, 0.1 µg/ml bleomycin; BL1.0, 1.0 µg/ml bleomycin; BL10, 10 µg/ml bleomycin; BL20, 20 µg/ml bleomycin; BL40, 40 µg/ml bleomycin; B20, 20 mg/kg baicalin; B40, 40 mg/kg baicalin; B60, 60 mg/kg baicalin; B80, 80 mg/kg baicalin.](MMR-21-06-2321-g04){#f5-mmr-21-06-2321}

![Baicalin decreases BLM-induced AKT and CaMKII protein phosphorylation and cell cycle progression *in vivo*. (A and B) BLM-induced upregulation of p-AKT and p-CaMKII protein expression was inhibited by baicalin (80 µg/ml) in lung fibroblasts (C) BLM promoted fibroblast cell cycle progression and increased the percentage of cells in the S and G~2~/M phases, while the proliferation indices were significantly decreased following baicalin treatment. (D) BLM-induced increase in \[Ca^2+^\]~i~ was significantly suppressed by baicalin (n=6) using laser scanning confocal microscopy (magnification, ×10). (E) Quantification of \[Ca^2+^\]~i~ levels. Data are presented as the mean ± SEM from ≥3 separate experiments. \*P\<0.05 and \*\*P\<0.01 vs. Con. ^\#\#^P\<0.01 vs. the BLM group. Con, control; BLM, bleomycin; BL, bleomycin; CaMKII, calcium/calmodulin-dependent kinase II; p, phosphorylated; B80, 80 mg/kg baicalin.](MMR-21-06-2321-g05){#f6-mmr-21-06-2321}
